Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Zollinger-Ellison Syndrome 1Tongue Neoplasms 1Stomatitis 1Somatostatinoma 1Radiation Injuries 1Paraganglioma 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gliosarcoma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1

Interventions

cabozantinib 3selpercatinib 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1sargramostim 1rovalpituzumab tesirine 1pentetreotide 1lutetium Lu 177 dotatate 1lenvatinib 1cixutumumab 1aldesleukin 1Vinorelbine 1Trastuzumab 1Tamoxifen 1Sirolimus 1Semaxinib 1Salts 1Restraint, Physical 1Radiotherapy 1Paclitaxel 1Octreotide 1Magnetic Resonance Spectroscopy 1Gefitinib 1Fluorodeoxyglucose F18 1FAPI-46 1Everolimus 1Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × Salts × CNS × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡